Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616677 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04616677 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 24 participants.
The verdict
NCT04616677, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetic of a single oral dose of JNJ-42847922 in adult participants with renal impairment compared with healthy participants with normal renal function.
Interventions
- DRUG JNJ-42847922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616677
The ClinicalTrials.gov registry entry for NCT04616677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-42847922 is the first listed.
NCT04616677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616677 about?
NCT04616677 is a clinical study titled "A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants". The purpose of this study is to evaluate the pharmacokinetic of a single oral dose of JNJ-42847922 in adult participants with renal impairment compared with healthy participants with normal renal function.
What is the current status of trial NCT04616677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-03-31. Estimated completion is 2022-10-18.
What interventions are being tested in trial NCT04616677?
The interventions under investigation include: JNJ-42847922 (DRUG).
Who is sponsoring clinical trial NCT04616677?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.